Arakawa's syndrome II[2] is an autosomal dominant metabolic disorder that causes a deficiency of the enzyme tetrahydrofolate-methyltransferase; affected individuals cannot properly metabolize methylcobalamin, a type of Vitamin B12.
Arakawa's syndrome II | |
---|---|
Other names | Methionine synthase deficiency, Tetrahydrofolate-methyltransferase deficiency syndrome, and N5-methylhomocysteine transferase deficiency.[1] |
methylcobalamin | |
Named after | Tsuneo Arakawa |
Presentation
editThis disorder causes neurological problems, including intellectual disability, brain atrophy and ventricular dilation, myoclonus, hypotonia, and epilepsy. [citation needed]
It is also associated with growth retardation, megaloblastic anemia, pectus excavatum, scoliosis, vomiting, diarrhea, and hepatosplenomegaly.[citation needed]
Genetics
editArakawa's syndrome II is inherited in an autosomal dominant manner. This means the defective gene responsible for disorder is located on an autosome, and one copy of the defective gene is sufficient to cause the disorder when inherited from a parent who has the disorder.[citation needed]
Diagnosis
editThis section is empty. You can help by adding to it. (October 2017) |
Management
editThis section is empty. You can help by adding to it. (October 2017) |
Eponym
editIt is called "Arakawa syndrome 2" after Tsuneo Arakawa (1949–2003), a Japanese Physician.;[2][3] in this context, "Arakawa syndrome 1" refers to Glutamate formiminotransferase deficiency.
References
edit- ^ Online Mendelian Inheritance in Man (OMIM): 156570
- ^ a b synd/235 at Who Named It?
- ^ Arakawa T; et al. (1967). "Megaloblastic anemia and mental retardation associated with hyperfolic-acidemia: probably due to N5 methanphetimite transferase deficiency". Tohoku J. Exp. Med. 93 (1): 1–22. doi:10.1620/tjem.93.1. PMID 5300832.
External links
edit- Arakawa's syndrome 2 at NIH's Office of Rare Diseases